Literature DB >> 28438434

Connective tissue growth factor decreases mitochondrial metabolism through ubiquitin-mediated degradation of mitochondrial transcription factor A in oral squamous cell carcinoma.

Wei-Ting Lai1, Yue-Ju Li1, Shi-Bei Wu2, Cheng-Ning Yang1, Tai-Sheng Wu1, Yau-Huei Wei3, Yi-Ting Deng4.   

Abstract

BACKGROUND/
PURPOSE: Deregulation of metabolic pathways is one of the hallmarks of cancer progression. Connective tissue growth factor (CTGF/CCN2) acts as a tumor suppressor in oral squamous cell carcinoma (OSCC). However, the role of CTGF in modulating cancer metabolism is still unclear.
METHODS: OSCC cells stably overexpressing CTGF (SAS/CTGF) and shRNA against CTGF (TW2.6/shCTGF) were established. Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were examined by the Seahorse XF24 analyzer. The expression of CTGF and mitochondrial biogenesis related genes was measured by real-time polymerase chain reaction or Western blot analysis.
RESULTS: CTGF decreased OCR, ECAR, adenosine triphosphate (ATP) generation, mitochondrial DNA (mtDNA), and mitochondrial transcription factor A (mtTFA) protein expression in OSCC cells. Overexpression of mtTFA restored CTGF-decreased OCR, ECAR, mtDNA copy number, migration and invasion of SAS/CTGF cells. Immunoprecipitation assay showed a higher level of ubiquitinated mtTFA protein after CTGF treatment. MG132, an inhibitor of proteasomal degradation, reversed the effect of CTGF on mtTFA protein expression in SAS cells.
CONCLUSION: CTGF can decrease glycolysis, mitochondrial oxidative phosphorylation, ATP generation, and mtDNA copy number by increasing mtTFA protein degradation through ubiquitin proteasome pathway and in turn reduces migration and invasion of OSCC cells. Therefore, CTGF may be developed as a potential additive therapeutic drug for oral cancer in the near future.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  CTGF; Metabolism; Mitochondrion; OSCC; mtTFA

Mesh:

Substances:

Year:  2017        PMID: 28438434     DOI: 10.1016/j.jfma.2017.04.003

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  3 in total

1.  HMOX1 silencing prevents doxorubicin-induced cardiomyocyte injury, mitochondrial dysfunction, and ferroptosis by downregulating CTGF.

Authors:  Jia Qian; Wenting Wan; Min Fan
Journal:  Gen Thorac Cardiovasc Surg       Date:  2022-08-25

2.  The Role of Increased Connective Tissue Growth Factor in the Pathogenesis of Oral Submucous Fibrosis and its Malignant Transformation-An Immunohistochemical Study.

Authors:  Aakruti Mahendra Shah; Kejal Jain; Rajiv S Desai; Shivani Bansal; Pankaj Shirsat; Pooja Prasad; Kshitija Bodhankar
Journal:  Head Neck Pathol       Date:  2021-02-05

3.  CCN2 Aggravates the Immediate Oxidative Stress-DNA Damage Response following Renal Ischemia-Reperfusion Injury.

Authors:  Floris A Valentijn; Sebastiaan N Knoppert; Georgios Pissas; Raúl R Rodrigues-Diez; Laura Marquez-Exposito; Roel Broekhuizen; Michal Mokry; Lennart A Kester; Lucas L Falke; Roel Goldschmeding; Marta Ruiz-Ortega; Theodoros Eleftheriadis; Tri Q Nguyen
Journal:  Antioxidants (Basel)       Date:  2021-12-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.